BI-3231

N/A

Report date: 2023/02/03 16:11:06
NME

Base Information

Drug NameBI-3231
Drug Alias NameBI-3231
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action17-beta-hydroxysteroid dehydrogenase 13 inhibitors
Targets17-beta-hydroxysteroid dehydrogenase 13
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim Pharma Gmbh & Co Kg
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim Pharma Gmbh & Co Kg
Inactive CompaniesN/A
Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A